Stock 0A87 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited London S.E.

Equities

0A87

US8740602052

Market Closed - London S.E.
Other stock markets
 11:28:45 2024-06-18 EDT 		5-day change 1st Jan Change
12.74 USD -2.52% Intraday chart for Takeda Pharmaceutical Company Limited -2.56% -10.44%
06-18 Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
06-18 Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 45.24 and 69.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
-10.44% 39.97B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.99% 803B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.72% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.94% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+11.07% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.96% 243B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 228B
A+
NOVARTIS AG Stock Novartis AG
+11.15% 217B
B-
AMGEN INC. Stock Amgen Inc.
+7.59% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.65% 155B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. 0A87 Stock
  5. Ratings Takeda Pharmaceutical Company Limited